BibTex RIS Kaynak Göster

Adenomatöz kolon polipli hastalarda oksidatif stres mekanizmasının paraoksonaz ve arilesteraz üzerinden değerlendirilmesi

Yıl 2013, Cilt: 23 Sayı: 4, 120 - 123, 01.01.2013

Öz

Amaç: Adenomatöz polip, rektum ve kolonda adenomların lümene doğru gelişimi ile karakterize klinik bir durumdur. Birçok dejeneratif ve tümöral hastalığın patogenezinde artmış oksidatif stres rol oynamaktadır. Bu çalışma adenomatöz kolon polipli hastalarda paraoksonaz, indüklenebilir paraoksonaz ve arilesteraz enzim aktivitelerinin tespiti ve oksidatif stres ile hastalığın patofizyolojisi arasındaki ilişkiyi ortaya koymak amacı ile planlanmıştır. Gereç ve yöntem: Namık Kemal Üniversitesi Araştırma ve Uygulama Hastanesi Gastroenteroloji Polikliniği’ne başvuran hastalardan kolon polipi saptananlar ve sağlıklı gönüllüler çalışmaya alındı. Paraoksonaz, indüklenebilir paraoksonaz ve arilesteraz düzeylerinin ölçümleri spektrofotometrik olarak yapıldı. Bulgular: Kolon polipli hastalar ile sağlıklı kontroller karşılaştırıldığında, kolon polipli hastalarda, paraoksonaz, indüklenebilir paraoksonaz aktiviteleri istatistiksel olarak anlamlı oranda düşük bulunurken, arilesteraz aktivitesinde istatistiksel olarak anlamlı fark bulunmadı. Sonuç: Kolon polipli hastalarda paraoksonaz ve indüklenebilir paraoksonaz aktivitesinin sağlıklı polülasyondan düşük bulunması, oksidan-antioksidan dengenin oksidan yönünde bozulmasının polipli hastalarda polip gelişimi ile yakın ilişki içinde olduğunu düşündürmektedir

Kaynakça

  • 1. Yamaner S. Colorectal polyps. Kolon Rektum Hast Derg 2007;17:1-8
  • 2. Naini BV, Odze RD. Advanced precancerous lesions (APL) in the colonic mucosa. Best Pract Res Clin Gastroenterol 2013;27:235- 56.
  • 3. Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381-6.
  • 4. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006;391:499- 510.
  • 5. Gutteridge JM. Biological origin of free radicals, and mechanisms of antioxidant protection. Chem Biol Interact 1994;91:133-40.
  • 6. Diaz-Castro J, Alferez MJ, Lopez-Aliaga I, et al. Influence of nutritional iron deficiency anemia on DNA stability and lipid peroxidation in rats. Nutrition 2008;24:1167-73.
  • 7. Hori A, Mizoue T, Kasai H, et al. Body iron store as a predictor of oxidative DNA damage in healthy men and women. Cancer Sci 2010;101:517-22.
  • 8. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
  • 9. Uysal S, Akyol S, Hasgül R, Armutcu F, Yigitoglu MR. Çok yönlü bir enzim: paraoksonaz. Yeni Tıp Derg 2011;28:136-41.
  • 10. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119-120:379-88.
  • 11. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W. Genetic Factors Influencing the Metabolism of Foreign Compounds: International Encyclopedia of Pharmacology and Therapeutics. Pergamon Press, New York 1992; 51-91.
  • 12. Harel M, Brumshtein B, Meged R, et al. 3-D structure of serum paraoxonase 1 sheds light on its activity, stability, solubility and crystallizability. Arh Hig Rada Toksikol 2007;58:347-53.
  • 13. Rodrigo L, Mackness B, Durrington PN, et al. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001;354:1-7.
  • 14. Gan KN, Smolen A, Eckerson HW, et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
  • 15. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126- 38.
  • 16. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
  • 17. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013;25:177- 83.
  • 18. Sweetser S, Smyrk TC, Sugumar A. Serrated polyps: critical precursors to colorectal cancer. Expert Rev Gastroenterol Hepatol 2011;5:627-35.
  • 19. Rainis T, Maor I, Lanir A, et al. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci 2007;52:526-30.
  • 20. Ikeda K, Mutoh M, Teraoka N, et al. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice. Cancer Sci 2011;102:79-87.
  • 21. Ferretti G, Bacchetti T, Moroni C, et al. Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 2003;1635:48-54.
  • 22. Başkol M, Başkol G, Koçer D. Mide kanserli hastalarda oksidan ve antioksidan parametreler ve birbiriyle ilişkileri. Türk Klinik Biyokim Derg 2007;5:83-9.
  • 23. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004;107:435-47.
  • 24. Kumon Y, Nakauchi Y, Suehiro T, et al. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 2002;9:160-4.
  • 25. Macri A, Versaci A, Loddo S, et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006;11:184-93.
  • 26. Feingold KR, Memon RA, Moser AH, et al. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998;139:307-15.
  • 27. Kiss E, Seres I, Tarr T, et al. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:83-91.
  • 28. Türkoğlu S, Gülcü Bulmuş F, Parmaksız A, ve ark. Metabolik Sendromlu Hastalarda Paraoksonaz 1 ve Arilesteraz Aktivite Düzeyleri. Fırat Tıp Derg 2008;13:110-5.
  • 29. Gursu MF, Ozdin M. Sigara içenlerde serum paraoksonaz (PON1) aktiviteleri ile malondialdehit düzeylerinin araştırılması. Fırat Tıp Derg 2002;7:732-7.
  • 30. Balci H, Genc H, Papila C, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26:155-60.
  • 31. Bulbuller N, Eren E, Ellidag HY, et al. Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. Neoplasma 2013;60:419-24.

The mechanism of oxidative stress in patients with adenomatous colon polyps, evaluation of the arylesterase and paraoxonase

Yıl 2013, Cilt: 23 Sayı: 4, 120 - 123, 01.01.2013

Öz

Objectives: Adenomatous polyps is characterized by the development of adenomas into the lumen in the rectum and colon. Increased oxidative stress plays a role in many degenerative diseases and tumor pathogenesis. The aim of this study in patients with adenoma- tous colon polyps paraoxonase, stimulated paraoxonase and arylesterase detection and reveal the relationship between oxidative stress and pathophysiology of the disease. Materials and methods: Patients admitted to Namik Kemal University Research and Training Hospital Gastroenterology Clinic with adenomatous polypossis and healty controls were studied. Paraoxonase, stimulated paraoxonase and arylesterase measurements were performed spectrophotometrically with manual methods. Results: The levels of pa- raoxonase and stimulated paraoxonase activity in patients with adenomatous polyps were found to be significantly lower than healthy controls, arylesterase activity were significantly higher than in healthy controls, but the difference was not statistically significant. Conclusion: A significant decrease in serum paraoxonase and stimulated paraoxonase activity lead to an increase in oxidative stress may play a role in the pathophysiology of adenomatous colon polyps

Kaynakça

  • 1. Yamaner S. Colorectal polyps. Kolon Rektum Hast Derg 2007;17:1-8
  • 2. Naini BV, Odze RD. Advanced precancerous lesions (APL) in the colonic mucosa. Best Pract Res Clin Gastroenterol 2013;27:235- 56.
  • 3. Federico A, Morgillo F, Tuccillo C, et al. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381-6.
  • 4. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006;391:499- 510.
  • 5. Gutteridge JM. Biological origin of free radicals, and mechanisms of antioxidant protection. Chem Biol Interact 1994;91:133-40.
  • 6. Diaz-Castro J, Alferez MJ, Lopez-Aliaga I, et al. Influence of nutritional iron deficiency anemia on DNA stability and lipid peroxidation in rats. Nutrition 2008;24:1167-73.
  • 7. Hori A, Mizoue T, Kasai H, et al. Body iron store as a predictor of oxidative DNA damage in healthy men and women. Cancer Sci 2010;101:517-22.
  • 8. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
  • 9. Uysal S, Akyol S, Hasgül R, Armutcu F, Yigitoglu MR. Çok yönlü bir enzim: paraoksonaz. Yeni Tıp Derg 2011;28:136-41.
  • 10. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999;119-120:379-88.
  • 11. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W. Genetic Factors Influencing the Metabolism of Foreign Compounds: International Encyclopedia of Pharmacology and Therapeutics. Pergamon Press, New York 1992; 51-91.
  • 12. Harel M, Brumshtein B, Meged R, et al. 3-D structure of serum paraoxonase 1 sheds light on its activity, stability, solubility and crystallizability. Arh Hig Rada Toksikol 2007;58:347-53.
  • 13. Rodrigo L, Mackness B, Durrington PN, et al. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001;354:1-7.
  • 14. Gan KN, Smolen A, Eckerson HW, et al. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
  • 15. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126- 38.
  • 16. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
  • 17. Hammoud SS, Cairns BR, Jones DA. Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 2013;25:177- 83.
  • 18. Sweetser S, Smyrk TC, Sugumar A. Serrated polyps: critical precursors to colorectal cancer. Expert Rev Gastroenterol Hepatol 2011;5:627-35.
  • 19. Rainis T, Maor I, Lanir A, et al. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci 2007;52:526-30.
  • 20. Ikeda K, Mutoh M, Teraoka N, et al. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice. Cancer Sci 2011;102:79-87.
  • 21. Ferretti G, Bacchetti T, Moroni C, et al. Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 2003;1635:48-54.
  • 22. Başkol M, Başkol G, Koçer D. Mide kanserli hastalarda oksidan ve antioksidan parametreler ve birbiriyle ilişkileri. Türk Klinik Biyokim Derg 2007;5:83-9.
  • 23. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 2004;107:435-47.
  • 24. Kumon Y, Nakauchi Y, Suehiro T, et al. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid 2002;9:160-4.
  • 25. Macri A, Versaci A, Loddo S, et al. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 2006;11:184-93.
  • 26. Feingold KR, Memon RA, Moser AH, et al. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998;139:307-15.
  • 27. Kiss E, Seres I, Tarr T, et al. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:83-91.
  • 28. Türkoğlu S, Gülcü Bulmuş F, Parmaksız A, ve ark. Metabolik Sendromlu Hastalarda Paraoksonaz 1 ve Arilesteraz Aktivite Düzeyleri. Fırat Tıp Derg 2008;13:110-5.
  • 29. Gursu MF, Ozdin M. Sigara içenlerde serum paraoksonaz (PON1) aktiviteleri ile malondialdehit düzeylerinin araştırılması. Fırat Tıp Derg 2002;7:732-7.
  • 30. Balci H, Genc H, Papila C, et al. Serum lipid hydroperoxide levels and paraoxonase activity in patients with lung, breast, and colorectal cancer. J Clin Lab Anal 2012;26:155-60.
  • 31. Bulbuller N, Eren E, Ellidag HY, et al. Diagnostic value of thiols, paraoxonase 1, arylesterase and oxidative balance in colorectal cancer in human. Neoplasma 2013;60:419-24.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Original Article
Yazarlar

Murat Aydn Bu kişi benim

Rafet Mete Bu kişi benim

Feti Tülübaş Bu kişi benim

Mustafa Oran Bu kişi benim

İlhan Bali Bu kişi benim

Oğuzhan Yıldırım Bu kişi benim

Filiz Turan Bu kişi benim

Ahmet Gürel Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2013
Yayımlandığı Sayı Yıl 2013 Cilt: 23 Sayı: 4

Kaynak Göster

Vancouver Aydn M, Mete R, Tülübaş F, Oran M, Bali İ, Yıldırım O, Turan F, Gürel A. Adenomatöz kolon polipli hastalarda oksidatif stres mekanizmasının paraoksonaz ve arilesteraz üzerinden değerlendirilmesi. Genel Tıp Derg. 2013;23(4):120-3.